The five studies included a total of 505 breast cancer patients with Gulati et al., 2017 [92], showing significantly increased levels of Gal-3 in patients treated with adjuvant anthracycline epirubicin combined with 5-FU and cyclophosphamide (median value 13.4 ng/mL (11.2, 16.0); p < 0.001) compared to baseline (median value 12.1 ng/mL (10.4, 14.0)). Here, LGALS3 is linked to breast cancer.